ZA200710785B - Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone - Google Patents

Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone

Info

Publication number
ZA200710785B
ZA200710785B ZA200710785A ZA200710785A ZA200710785B ZA 200710785 B ZA200710785 B ZA 200710785B ZA 200710785 A ZA200710785 A ZA 200710785A ZA 200710785 A ZA200710785 A ZA 200710785A ZA 200710785 B ZA200710785 B ZA 200710785B
Authority
ZA
South Africa
Prior art keywords
ionone
carveol
carvacrol
borneol
thymol
Prior art date
Application number
ZA200710785A
Other languages
English (en)
Inventor
Remmal Adnane
Original Assignee
Advanced Scient Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developments filed Critical Advanced Scient Developments
Publication of ZA200710785B publication Critical patent/ZA200710785B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200710785A 2005-05-13 2007-12-12 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone ZA200710785B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001314 WO2006120495A1 (fr) 2005-05-13 2005-05-13 Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol

Publications (1)

Publication Number Publication Date
ZA200710785B true ZA200710785B (en) 2009-06-24

Family

ID=35427309

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710785A ZA200710785B (en) 2005-05-13 2007-12-12 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone

Country Status (16)

Country Link
US (2) US20080171768A1 (de)
EP (2) EP1883452B1 (de)
JP (1) JP5073651B2 (de)
CN (2) CN101193682B (de)
AP (1) AP2437A (de)
AT (1) ATE554827T1 (de)
BR (2) BRPI0610123A2 (de)
CA (2) CA2606887C (de)
DK (2) DK1883452T3 (de)
EA (1) EA015168B1 (de)
ES (2) ES2386292T3 (de)
MA (2) MA29908B1 (de)
PT (2) PT1883452E (de)
TN (2) TNSN07423A1 (de)
WO (3) WO2006120495A1 (de)
ZA (1) ZA200710785B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113042A1 (en) * 2006-09-05 2008-05-15 Chu Kee Hung Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof
US20080293648A1 (en) * 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
EA019746B1 (ru) 2009-09-24 2014-05-30 Юнилевер Нв Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности
US9408870B2 (en) 2010-12-07 2016-08-09 Conopco, Inc. Oral care composition
WO2013064360A2 (en) 2011-11-03 2013-05-10 Unilever N.V. A personal cleaning composition
CN102579449B (zh) * 2012-03-30 2013-08-07 厦门大学 一种可提高肿瘤对紫杉醇敏感性的联合用药
GB201404505D0 (en) * 2013-09-06 2014-04-30 Mars Inc Oral anti-parasitic composition
KR20170052626A (ko) 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
CN107405404A (zh) * 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
CA2988082C (en) 2015-06-01 2020-09-29 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
CN105147647A (zh) * 2015-08-19 2015-12-16 华南理工大学 右旋龙脑作为抗肿瘤药物增敏剂的应用
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
WO2018176079A1 (en) * 2017-03-28 2018-10-04 Iriccorgpharm Pty Ltd Berberine alkaloids in the prevention and/or treatment of intestinal disease
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
CN112972437B (zh) * 2021-02-19 2022-03-25 沈阳伟嘉生物技术有限公司 一种包含碘硝酚的长效外用制剂及其制备方法和用途
CN121550195A (zh) * 2026-01-21 2026-02-24 哈尔滨医科大学 β-紫罗兰酮在制备肿瘤免疫调节剂中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
DE19509697A1 (de) * 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP1137426B1 (de) * 1998-12-07 2005-10-26 Ecosmart Technologies, Inc. Brustkrebsbehandlung mittels natürlicher ätherischer öle
US6536268B1 (en) * 1999-11-01 2003-03-25 Siemens Vdo Automotive Corporation Utilizing increasing width for identification voltages
DE10007771A1 (de) * 2000-02-14 2001-08-23 Kleine & Steube Entoxin Gmbh Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1331946A2 (de) * 2000-11-09 2003-08-06 Jörg-Peter Schür Synergistisches, aromastoffhaltiges arzneimittel mit antagonistischer, regenerativer und/oder protagonistischer dekontaminativer wirkung
EP1351678A2 (de) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Behandlung von neoplastischen erkrankungen mit incensol und/oder furanogermacren
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
US6921539B2 (en) * 2002-02-20 2005-07-26 Dusan Ninkov Antimicrobial therapeutic compositions and method of use
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
AU2003296937A1 (en) * 2002-12-10 2004-06-30 Biosynexus Incorporated Topical anti-infective formulations
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CN100343223C (zh) * 2005-03-07 2007-10-17 常州市智能动物药业有限公司 百里酚或香芹酚的酯类化合物、制备方法及其药物活性组合物

Also Published As

Publication number Publication date
CA2608061A1 (fr) 2006-11-16
CN101193682B (zh) 2012-06-13
BRPI0610123A2 (pt) 2012-09-25
EA015168B1 (ru) 2011-06-30
CA2606887A1 (fr) 2006-11-16
JP5073651B2 (ja) 2012-11-14
ATE554827T1 (de) 2012-05-15
CA2606887C (fr) 2014-07-15
CA2608061C (fr) 2014-07-15
WO2006120564A1 (fr) 2006-11-16
PT1883452E (pt) 2013-02-18
EA200702486A1 (ru) 2008-06-30
WO2006120568A3 (fr) 2007-08-23
PT1879656E (pt) 2012-07-25
EP1883452B1 (de) 2012-12-19
ES2399348T3 (es) 2013-03-27
AP2007004228A0 (en) 2007-12-31
MA29573B1 (fr) 2008-06-02
US20080171709A1 (en) 2008-07-17
CN101193682A (zh) 2008-06-04
MA29908B1 (fr) 2008-11-03
WO2006120495A1 (fr) 2006-11-16
TNSN07426A1 (fr) 2009-03-17
EP1879656B1 (de) 2012-04-25
ES2386292T3 (es) 2012-08-16
TNSN07423A1 (fr) 2009-03-17
DK1879656T3 (da) 2012-07-23
AP2437A (en) 2012-08-31
DK1883452T3 (da) 2013-02-25
JP2008540505A (ja) 2008-11-20
EP1879656A1 (de) 2008-01-23
CN101175532B (zh) 2011-12-28
CN101175532A (zh) 2008-05-07
EP1883452A2 (de) 2008-02-06
US20080171768A1 (en) 2008-07-17
WO2006120568A2 (fr) 2006-11-16
BRPI0610130A2 (pt) 2012-09-25

Similar Documents

Publication Publication Date Title
ZA200710785B (en) Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone
WO2006120567A3 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
TWI366460B (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
AP2008004525A0 (en) Compositions and methods comprising terpene mixtures selected from thymol, eugenol, geraniol, citral, and L-carvone
ZA200710734B (en) Compositions for drug delivery
PL3075401T3 (pl) Środek konserwujący dla kompozycji kosmetycznych, toaletowych i farmaceutycznych
AP2416A (en) Stabilized pharmaceutical compositions comprising fesoterodine.
WO2008024490A3 (en) Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IL190915A0 (en) Dry formulations of aripiprazole
WO2010021607A3 (en) Pharmaceutical formulation
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
TNSN07425A1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.
IL185197A0 (en) Ophthalmological pharmaceutical compositions
WO2007084221A9 (en) Methods and apparatus for identifying subject matter in view data
IL192206A0 (en) Topical mecamylamine formulations for ocular administration and uses thereof
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
IL201037A (en) Solid crystalline forms of (e) –1– (4– (r1, s2, r3) –4,3,2,1 - tetrahydroxybutyl) - h1– imidazole-2-yl) Oxide ethanol and pharmaceutical preparations containing them
WO2007009606A3 (de) Desinfektionsmittel enthaltend eine kombination biozider und ein keratolytikum
EP1811967A4 (de) Verfahren und formulierungen zur herstellung von pharmazeutischen zusammensetzungen mit bupropion
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2008062274A3 (en) Pharmaceutical formulations of nsaids for parentral use
EP1853238A4 (de) Pharmazeutische formulierungen mit 17-allylamino-17-demethoxygeldanamycin